6-(chloromethyl)-2-pyridin-2-yl-pyrimidin-4-ol | 680216-41-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(chloromethyl)-2-pyridin-2-yl-pyrimidin-4-ol
• 英文别名: 6-(Chloromethyl)-2-(pyridin-2-yl)pyrimidin-4-ol；4-(chloromethyl)-2-pyridin-2-yl-1H-pyrimidin-6-one
• CAS: 680216-41-5
• 化学式: C₁₀H₈ClN₃O
• 分子量: 221.646
• InChiKey: PQQSVAZRXLMNNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(chloromethyl)-2-pyridin-2-yl-pyrimidin-4-ol 在 三氯氧磷 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 1.0h， 生成 4-chloro-6-(chloromethyl)-2-pyridin-2-yl-pyrimidine
  参考文献：
  名称：

  WO2007/80382

  摘要：

  公开号：
• 作为产物：
  描述：

  吡啶-2-羧酰胺 、 4-氯乙酰乙酸甲酯 在 sodium ethanolate 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 生成 6-(chloromethyl)-2-pyridin-2-yl-pyrimidin-4-ol
  参考文献：
  名称：

  WO2007/80382

  摘要：

  公开号：

文献信息

• Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
  申请人：Borchardt Allen

  公开号：US20050176701A1

  公开（公告）日：2005-08-11

  The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R 1 and R 2 , are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  这项发明涉及公式1的化合物，以及其药学上可接受的盐、溶剂化合物、前药和代谢物，其中W、Z、R1和R2如本文所定义。该发明还涉及通过给哺乳动物施用公式1的化合物来治疗丙型肝炎病毒的方法，以及用于治疗这类疾病的含有公式1化合物的药物组合物。该发明还涉及制备公式1化合物的方法。
• Use of Metal Complex Compounds as Oxidation Catalysts
  申请人：Schlingloff Gunther

  公开号：US20090044345A1

  公开（公告）日：2009-02-19

  The present invention relates to the use, as oxidation catalysts, of metal complex compounds having tetradentate ligands of formula (2) wherein all substitutents have the meanings as defined in Claim 1 . The present invention relates also to formulations comprising such metal complex compounds, to novel metal complex compounds and to novel ligands.

  本发明涉及将具有四齿配体的金属配合物化合物用作氧化催化剂，其化学式为（2），其中所有取代基的含义如权利要求1中定义的。本发明还涉及包含这种金属配合物化合物的配方，以及新型金属配合物和新型配体。
• INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME
  申请人：Borchardt Allen

  公开号：US20060189681A1

  公开（公告）日：2006-08-24

  The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R 1 and R 2 , are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  本发明涉及式1的化合物以及其药学上可接受的盐、溶剂合物、前药和代谢物，其中W、Z、R1和R2如本文所定义。本发明还涉及通过给哺乳动物投予式1的化合物来治疗丙型肝炎病毒的方法，以及包含式1的化合物的用于治疗此类疾病的制药组合物。本发明还涉及制备式1的化合物的方法。
• MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY
  申请人：Dishington Allan Paul

  公开号：US20110034454A1

  公开（公告）日：2011-02-10

  A compound of formula (I) or a salt, ester or prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.

  化合物的公式（I）或其盐、酯或前药，它们的制备过程，包含它们的药物组合物以及它们在治疗中的用途，例如在治疗增生性疾病如癌症中，特别是在由mTOR激酶和/或一个或多个PI3K酶介导的疾病中。
• Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor
  作者：M. Raymond V. Finlay、David Buttar、Susan E. Critchlow、Allan P. Dishington、Shaun M. Fillery、Eric Fisher、Steve C. Glossop、Mark A. Graham、Trevor Johnson、Gillian M. Lamont、Simon Mutton、Paula Perkins、Kurt G. Pike、Anthony M. Slater.

  DOI：10.1016/j.bmcl.2012.04.036

  日期：2012.6

  High throughput screening to identify inhibitors of the mTOR kinase revealed sulfonyl-morpholino-pyrimidine 1 as an attractive start point. The compound displayed good physicochemical properties and selectivity over related kinases such as PI3K alpha. Library preparation of related analogs allowed the establishment of additional SAR understanding and in particular the requirement for a key hydrogen bond donor motif at the 4-position of the phenyl ring in compounds such as indole 19. Isosteric replacement of the indole functionality led to the identification of urea compounds such as 32 that show good levels of mTOR inhibition in both enzyme and cellular assays. (C) 2012 Elsevier Ltd. All rights reserved.